Bank of New York Mellon
KROS icon

Bank of New York Mellon’s Keros Therapeutics KROS Stock Holding History

Bank of New York Mellon’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
103,339
-17,605
-15% -$196K ﹤0.01% 3301
2026
Q1 		$1.34M Sell
120,944
-638
-0.5% -$9.85K ﹤0.01% 3038
2025
Q4 		$2.48M Buy
121,582
+10,700
+10% +$188K ﹤0.01% 2722
2025
Q3 		$1.75M Buy
110,882
+1,533
+1% +$22.6K ﹤0.01% 2872
2025
Q2 		$1.46M Buy
109,349
+11,594
+12% +$157K ﹤0.01% 2901
2025
Q1 		$996K Sell
97,755
-123
-0.1% -$1.43K ﹤0.01% 3074
2024
Q4 		$1.55M Buy
97,878
+2,462
+3% +$128K ﹤0.01% 2881
2024
Q3 		$5.54M Sell
95,416
-22,972
-19% -$1.13M ﹤0.01% 2247
2024
Q2 		$5.41M Buy
118,388
+18,755
+19% +$1.01M ﹤0.01% 2306
2024
Q1 		$6.6M Buy
99,633
+5,129
+5% +$304K ﹤0.01% 2181
2023
Q4 		$3.76M Sell
94,504
-49,905
-35% -$1.56M ﹤0.01% 2510
2023
Q3 		$4.6M Buy
144,409
+42,771
+42% +$1.6M ﹤0.01% 2357
2023
Q2 		$4.08M Sell
101,638
-30,939
-23% -$1.36M ﹤0.01% 2435
2023
Q1 		$5.66M Buy
132,577
+38,650
+41% +$1.95M ﹤0.01% 2232
2022
Q4 		$4.51M Buy
93,927
+19,410
+26% +$907K ﹤0.01% 2396
2022
Q3 		$2.8M Buy
74,517
+27,744
+59% +$962K ﹤0.01% 2620
2022
Q2 		$1.29M Buy
46,773
+321
+0.7% +$14.1K ﹤0.01% 3076
2022
Q1 		$2.53M Buy
46,452
+152
+0.3% +$7.8K ﹤0.01% 2807
2021
Q4 		$2.71M Buy
46,300
+3,345
+8% +$167K ﹤0.01% 2807
2021
Q3 		$1.7M Buy
42,955
+4,595
+12% +$164K ﹤0.01% 3088
2021
Q2 		$1.63M Sell
38,360
-4,369
-10% -$237K ﹤0.01% 3136
2021
Q1 		$2.63M Sell
42,729
-124
-0.3% -$7.86K ﹤0.01% 2768
2020
Q4 		$3.02M Buy
42,853
+24,748
+137% +$1.56M ﹤0.01% 2605
2020
Q3 		$699K Sell
18,105
-85
-0.5% -$3.37K ﹤0.01% 3319
2020
Q2 		$682K Buy
+18,190
New +$560K ﹤0.01% 3311

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
NC
nVerses Capital Wellington, Florida $65M AUM

Bank of New York Mellon's KROS Position: Q2 2026 in Review

Bank of New York Mellon reduced its Keros Therapeutics (KROS) stake by 15% in Q2 2026, selling an estimated $196K and leaving 103,339 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

Bank of New York Mellon first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.6M in Q1 2024. 35 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Bank of New York Mellon held 103,339 shares of Keros Therapeutics worth $1.11M as of Q2 2026.
  • Bank of New York Mellon sold 17,605 Keros Therapeutics shares in Q2 2026, an estimated $196K.
  • Keros Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3301 holding.
  • Bank of New York Mellon first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Bank of New York Mellon's Keros Therapeutics position peaked at $6.6M in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.